Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Aurora Pharmaceutical, Inc.
WARNING LETTER
•Aurora Pharmaceutical, Inc.•March 11, 2025

Aurora Pharmaceutical, Inc. – FDA Warning Letter, Mar 11, 2025

Record Details

The FDA issued a Warning Letter to Aurora Pharmaceutical on February 7, 2025, regarding false or misleading promotional communications for their FDA-approved products: Altren® (altrenogest), SwineMate® (altrenogest), and Barrier™ for dogs (imidacloprid and moxidectin). The FDA reviewed the company website and linked webpages, identifying violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) sections 502(a), 502(n), 201(n), and 21 CFR 202.1(e)(5), which constitute misbranding.

The core issue is the omission or downplaying of serious safety warnings in promotional materials. For Altren® and SwineMate®, which have significant human user safety risks (e.g., skin absorption leading to menstrual cycle disruption or prolonged pregnancy, requiring specific glove types), the website and product sheets prominently feature benefits while omitting or presenting risk information in a less prominent, smaller font, or on a separate page, lacking fair balance. Print advertisements for Altren® also omit crucial human safety warnings or present them in an unreadable font.

For Barrier™ for dogs, the website omits the boxed warning regarding oral exposure in dogs and topical exposure in children, as well as other animal and human safety information. The product sheet for Barrier™ for dogs also lacks fair balance, with extensive benefit information preceding a

Company
Aurora Pharmaceutical, Inc.
Inspection date
March 11, 2025
Product type
Veterinary
Office
Center for Veterinary Medicine
People
  • Linda Walter-grimm
  • Christopher Loss
View Company Profile

ID · 9f2a86f7-4afa-4597-8bb9-f7a8163b5ac1

Violation Codes9
21 U.S.C. 352(a)21 U.S.C. 352(n)21 U.S.C. 321(n)21 CFR 202.1(e)(5)21 CFR 202.1(e)(7)(viii)21 CFR 202.1(e)(7)(xii)21 CFR 201.105(d)(1)21 CFR 202.1(e)(1)21 U.S.C. 331(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Aurora Pharmaceutical, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.